A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch. Vik Bajaj is Managing Director at Foresite Capital Management (which led Xaira's funding) and Cofounder and CEO at Foresite Labs (which helped incubate it, along with ARCH Venture Partners). He takes us behind the scenes, and shares his worldview on the role of advanced computing technology in drug development.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. (00:00:00)

2. Biotech Industry Convergence (00:00:04)

3. Accelerating Biotech Product Development Cycle (00:15:55)

4. Regulatory Innovation and Biotech Investments (00:25:59)

5. Biotech Funding for Healthcare Innovation (00:42:42)